Execution Plan Sample Clauses

An Execution Plan clause outlines the specific steps, timelines, and responsibilities required to carry out a project or contract. It typically details the sequence of tasks, assigns duties to relevant parties, and sets deadlines for completion, ensuring all stakeholders understand their roles and the overall schedule. By providing a clear roadmap for implementation, this clause helps coordinate efforts, manage expectations, and reduce the risk of misunderstandings or delays during the execution phase.
Execution Plan. The Design Team shall submit to Contra Costa Community College District within thirty (30) days of contract award, a BIM Execution Plan. The BIM Execution Plan’s template shall be provided by the District. The BIM Execution Plan will be reviewed and approved by Contra Costa Community College District within fourteen (14) days of it being submitted.
View SourceView Similar (2)
Execution Plan. RadioLoyalty released the production version of the broadcaster platform on September 9, 2011. Since that time, we have grown revenues considerably. As of September 9, 2011 the system operated to its design specifications, which now enables us to aggressively solicit and onboard radio broadcasters to our platform.
View Source
Execution Plan. Covering all requirements, timelines, as well as identification of societies and opinion leaders to support the process. (Hereinafter referred to as the "Services"). medeuronet UK is incorporated in England & Wales with its registered office at the Leather Market, ▇▇/▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇ ▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇▇▇▇. Company registration: 06591143. ▇▇▇.▇▇▇▇▇▇▇▇▇▇.▇▇▇ Tel: +▇▇ ▇▇▇ ▇▇▇ ▇▇▇▇ Email: ▇▇▇▇▇▇▇@▇▇▇▇▇▇▇▇▇▇.▇▇▇ BDV_01_FOR12_medeuronet Consulting Services Letter of Agreement Template_med UK_V1
View Source
Execution Plan. The following information is required to be submitted as part of the Contractor’s Execution Plan submittal: • Within 10 business days of the Contractor’s Agreement execution, a detailed Execution Plan that describes how the Contractor proposes to conduct the requested work activities must be submitted to the Owner and the Owner’s Representative. o Owner - ▇▇▇▇▇▇ ▇▇▇▇▇▇▇: ▇▇▇▇▇▇▇▇▇▇▇@▇▇▇▇▇.▇▇▇ o Owner’s Representative - ▇▇▇▇▇ ▇▇▇▇▇▇▇ and ▇▇▇▇▇▇ ▇▇▇▇: ▇▇▇▇▇.▇▇▇▇▇▇▇@▇▇▇▇▇▇.▇▇▇ and ▇▇▇▇▇▇.▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇ • The Execution Plan must, at a minimum, include the following: o Identification of all personnel, equipment, and materials to be used. o Identification of all subcontractors (if any) to be used and their role in conducting elements of the Work. Owner’s Representative must give written approval of all subcontractors prior to their entering the facility. o Truck traffic routes, staging areas, personnel decontamination stations, and parking areas for Site personnel. o Proposed waste management approach (including collection, segregation, and containerization of wastes, transportation & disposal for all waste, and which disposal facility to be used) o Proposed execution schedule showing the work days and hours within 6:00 a.m. – 6:00 p.m., Monday – Friday (unless otherwise approved by the Owner). o Provide names and resumes of its nominated key personnel (such as, but not limited to, Project Manager, Site Supervisor, and Site Health and Safety Officer) for Owner’s Representative acceptance.
View Source
Execution Plan. The following execution plan of the Forward Sales Plan supplements and forms part of, and is subject to, the additional provisions of the Forward Sale Plan under other Forward Sales Documents. At any time and from time to time during the Plan Effective Period (as defined in the Transaction Acknowledgment), Party A (or an affiliate of Party A) shall establish the Initial Hedge, with respect to a number of Shares equal to or less than the Maximum Number of Shares (as defined in the Transaction Acknowledgement), in accordance with the Transaction Acknowledgement and the following conditions:
View Source
Execution Plan. The estimated Schedule for executing “ARACO” website starting from design time to the final hand-over is Six (6)
View Source
Execution Plan. Employment visa with profession as Computer Programmer / Computer Engineer will be provided within 15-25 working days (Degree certificate attestation 10 days, Visa processing 15 days) from the date of receiving first installment. For those who don't have degree in hand (Employment visa will be provided in 15 working days) and want to join immediately, we can process their visa on non technical profession, later they can change it to technical with their own expenses when the attested degree is ready. One time visa and one ticket expenses are included in the fee.
View Source

Related to Execution Plan

  • Transition Plan In the event of termination by the LHIN pursuant to this section, the LHIN and the HSP will develop a Transition Plan. The HSP agrees that it will take all actions, and provide all information, required by the LHIN to facilitate the transition of the HSP’s clients.

  • Action Plan A form documenting key tasks that must be completed to create change. Action 16 Plans detail how resources are to be used to get the planned work done.

  • Implementation Plan The Authority shall cause to be prepared an Implementation Plan meeting the requirements of Public Utilities Code Section 366.2 and any applicable Public Utilities Commission regulations as soon after the Effective Date as reasonably practicable. The Implementation Plan shall not be filed with the Public Utilities Commission until it is approved by the Board in the manner provided by Section 4.9.

  • Staffing Plan The Board and the Association agree that optimum class size is an important aspect of the effective educational program. The Polk County School Staffing Plan shall be constructed each year according to the procedures set forth in Board Policy and, upon adoption, shall become Board Policy.

  • Transition Agreement 12.8.1 In the event of termination of this Agreement, whether in its entirety or with respect to the Terminated Territory, Ablynx and AbbVie shall negotiate in good faith the terms and conditions of a written transition agreement (the “Transition Agreement”) pursuant to which AbbVie and Ablynx will effectuate and coordinate a smooth and efficient transition of relevant obligations and rights to Ablynx as reasonably necessary for Ablynx to exercise its licenses pursuant to Sections 12.6 and 12.7 with respect to the Licensed Products after termination of this Agreement (in its entirety or with respect to the Terminated Territory, as applicable) as and to the extent set forth in this Article 12. For purposes of clarity, AbbVie shall not be required to Manufacture or have Manufactured the Licensed Products by or on behalf of Ablynx as part of the Transition Agreement. CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...***...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 12.8.2 The Transition Agreement shall provide that in the event of a termination of this Agreement in its entirety by AbbVie pursuant to Section 12.3 or by Ablynx in its entirety pursuant to Section 12.2.1, AbbVie shall: (i) where permitted by Applicable Law, transfer to Ablynx all of its right, title, and interest in all Regulatory Documentation then Controlled by AbbVie and in its name applicable to the Licensed Products in the Territory that are the subject of an exclusive license grant in Section 12.6.1(iii); (ii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect the transfer set forth in clause (i) above; (iii) unless expressly prohibited by any Regulatory Authority, transfer control to Ablynx of all Clinical Studies being Conducted by AbbVie as of the effective date of termination and continue to Conduct such Clinical Studies, […***…], for up to […***…] to enable such transfer to be completed without interruption of any such Clinical Study; provided, that (a) Ablynx shall not have any obligation to continue any Clinical Study unless required by Applicable Law, in which case Ablynx, if it wishes to terminate such Clinical Study, shall continue such Clinical Study […***…] until such time that Applicable Law allows such trial to be terminated (with Ablynx taking all reasonable steps to promptly terminate such Clinical Study and minimize all costs and expenses), and (b) with respect to each Clinical Study for which such transfer is expressly prohibited by the applicable Regulatory Authority, if any, AbbVie shall continue to Conduct such Clinical Study to completion, […***…]; (iv) assign (or cause its Affiliates to assign) to Ablynx all agreements with any Third Party with respect to the conduct of pre-clinical Development activities, Manufacturing or Clinical Studies for the Licensed Products, including agreements with contract research organizations, contract manufacturing organizations, clinical sites, and investigators, unless, with respect to any such agreement, such agreement (a) expressly prohibits such assignment, in which case AbbVie shall cooperate with Ablynx in reasonable respects to secure the consent of the applicable Third Party to such assignment, or (b) covers Clinical Studies for Combination Products in which any active ingredient that is not a Licensed Compound is covered by Patents Controlled by AbbVie or any of its Affiliates or covers products covered by Patents Controlled by AbbVie or any of its Affiliates in addition to the Licensed Products, in which case AbbVie shall, […***…], cooperate with Ablynx in all reasonable respects to facilitate the execution of a new agreement between Ablynx and the applicable Third Party; and (v) transfer to Ablynx all existing clinical supplies of the Licensed Compound or Licensed Product in the possession of AbbVie at the time of termination, which shall be […***…]. CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...***...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. In the event this Agreement is partially terminated or terminated in its entirety by Ablynx pursuant Section 12.2.1, then any actions or activities set forth in the Transition Agreement shall be […***…]. 12.8.3 The Transition Agreement shall provide that in the event of a termination of this Agreement with respect to a country or other jurisdiction by AbbVie pursuant to Section 12.3.2 or with respect to a Terminated Territory by Ablynx pursuant to Section 12.2.2 (but not in the case of any termination of this Agreement in its entirety), AbbVie shall in a reasonable amount of time following Ablynx’s request: (i) where permitted by Applicable Law, transfer to Ablynx all of its right, title, and interest in all Regulatory Approvals owned by AbbVie and then in its name that is solely applicable to the Terminated Territory and to the Licensed Products that are the subject of an exclusive license grant in Section 12.7.2, as such Regulatory Approvals exists as of the effective date of such termination of this Agreement with respect to such Terminated Territory; provided, that AbbVie retains a license and right of reference under any Regulatory Approval transferred pursuant to this clause as necessary or reasonably useful for AbbVie to Commercialize Licensed Products in the Territory, Develop Licensed Products in support of such Commercialization, or Manufacture Licensed Products in support of such Development or Commercialization; (ii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect the transfer set forth in clause (i) above; (iii) grant Ablynx a right of reference to all Regulatory Documentation then owned by AbbVie and in AbbVie’s name that are not transferred to Ablynx pursuant to clause (i) above that are necessary or reasonably useful for Ablynx, any of its Affiliates or sublicensees to Develop or Commercialize any Licensed Products that are the subject of the license grant in Section 12.7.2, as such Regulatory Documentation exists as of the effective date of such termination of this Agreement with respect to such Terminated Territory.